Telix Pharmaceuticals Limited (ASX:TLX)
Australia
· Delayed Price · Currency is AUD 10.75
+0.66 (6.54%)
At close: Mar 6, 2026
Telix Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 803.79 | 516.55 | 332.98 | 108.81 | 5.52 | Upgrade
|
| Revenue Growth (YoY) | 55.61% | 55.13% | 206.01% | 1870.12% | 37.33% | Upgrade
|
| Cost of Revenue | 421.95 | 197.06 | 129.7 | 44.29 | 1.85 | Upgrade
|
| Gross Profit | 381.85 | 319.49 | 203.28 | 64.52 | 3.67 | Upgrade
|
| Selling, General & Admin | 192.56 | 135.52 | 83.13 | 59.2 | 34.16 | Upgrade
|
| Research & Development | 171.25 | 127.93 | 85.32 | 55.06 | 24.82 | Upgrade
|
| Other Operating Expenses | -1.25 | 0.16 | -0.14 | 0.63 | - | Upgrade
|
| Operating Expenses | 362.56 | 263.61 | 168.3 | 114.89 | 62.75 | Upgrade
|
| Operating Income | 19.29 | 55.88 | 34.98 | -50.37 | -59.08 | Upgrade
|
| Interest Expense | -13.76 | -4.79 | -0.52 | -0.22 | -0.12 | Upgrade
|
| Interest & Investment Income | 5.83 | 7.18 | 0.67 | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.56 | 11.9 | -0.73 | -0.76 | 1.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -27.11 | -19.65 | -8.57 | -4.33 | 10.25 | Upgrade
|
| EBT Excluding Unusual Items | -16.32 | 50.52 | 25.83 | -55.68 | -47.71 | Upgrade
|
| Merger & Restructuring Charges | - | -5.75 | - | - | - | Upgrade
|
| Asset Writedown | -0.57 | 0.48 | -0.55 | - | - | Upgrade
|
| Other Unusual Items | 11.62 | -7.33 | -22.69 | -11.36 | -10.8 | Upgrade
|
| Pretax Income | -5.27 | 37.92 | 2.59 | -67.03 | -58.51 | Upgrade
|
| Income Tax Expense | 1.86 | 4.23 | -1.61 | 3.71 | 0.03 | Upgrade
|
| Net Income | -7.13 | 33.69 | 4.21 | -70.74 | -58.54 | Upgrade
|
| Net Income to Common | -7.13 | 33.69 | 4.21 | -70.74 | -58.54 | Upgrade
|
| Net Income Growth | - | 700.50% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 338 | 331 | 319 | 311 | 282 | Upgrade
|
| Shares Outstanding (Diluted) | 338 | 345 | 324 | 311 | 282 | Upgrade
|
| Shares Change (YoY) | -2.12% | 6.64% | 4.21% | 10.08% | 9.69% | Upgrade
|
| EPS (Basic) | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 | Upgrade
|
| EPS (Diluted) | -0.02 | 0.10 | 0.01 | -0.23 | -0.21 | Upgrade
|
| EPS Growth | - | 650.77% | - | - | - | Upgrade
|
| Free Cash Flow | -42.99 | 18.37 | 7.97 | -48.26 | -44.11 | Upgrade
|
| Free Cash Flow Per Share | -0.13 | 0.05 | 0.03 | -0.15 | -0.16 | Upgrade
|
| Gross Margin | 47.50% | 61.85% | 61.05% | 59.29% | 66.46% | Upgrade
|
| Operating Margin | 2.40% | 10.82% | 10.51% | -46.29% | -1069.60% | Upgrade
|
| Profit Margin | -0.89% | 6.52% | 1.26% | -65.01% | -1059.90% | Upgrade
|
| Free Cash Flow Margin | -5.35% | 3.56% | 2.39% | -44.35% | -798.67% | Upgrade
|
| EBITDA | 32.46 | 59.64 | 38.17 | -47.3 | -55.79 | Upgrade
|
| EBITDA Margin | 4.04% | 11.54% | 11.46% | -43.47% | - | Upgrade
|
| D&A For EBITDA | 13.17 | 3.75 | 3.19 | 3.07 | 3.29 | Upgrade
|
| EBIT | 19.29 | 55.88 | 34.98 | -50.37 | -59.08 | Upgrade
|
| EBIT Margin | 2.40% | 10.82% | 10.51% | -46.29% | - | Upgrade
|
| Effective Tax Rate | - | 11.16% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.